Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers of SLE and RA Patients Under the Rituximab Treatment

Introduction: Lately, the use of biological therapy in various autoimmune diseases is increasing. The ideal marker for monitoring the effects of modern therapy is still non-existent. Aim: To investigate early response biomarkers of SLE and RA patients under the rituximab treatment are in research ph...

Full description

Saved in:
Bibliographic Details
Published in:Medicinski arhiv 2019-12, Vol.73 (6), p.374-377
Main Authors: Zecevic, Lamija, Mekic, Mevludin, Subasic, Djemo, Hadzibulic, Majda, Isak, Edmira, Emina, Emina, Selmanovic, Kenan
Format: Article
Language:English
Subjects:
Autoimmune diseases
Biomarkers
Clinical outcomes
Immunotherapy
Investigations
Lupus
Monoclonal antibodies
Original Paper
Rheumatoid arthritis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Lately, the use of biological therapy in various autoimmune diseases is increasing. The ideal marker for monitoring the effects of modern therapy is still non-existent. Aim: To investigate early response biomarkers of SLE and RA patients under the rituximab treatment are in research phase and each new investigations offer new and original useful data. Material and Methods: Immunophenotyping of cells was carried out by a standard method of sample preparation. We investigated by flow cytometric analyses expression of NK and CD19+ cells at ten SLE and five RA patients before and after treatment with rituximab, in laboratory of Department of Clinical immunology in the Clinical Centre University of Sarajevo. Results: In both cases, SLE and RA patients, reduced number of CD16+ parameter indicates lower cytotoxic activity of NK cells. Increased number of B cells indicates higher pathological activity leading to severe autoimmune disease allegation. Conclusion: Determining the proportion of NK and B will be useful diagnostic tool in therapeutic strategy, and also in monitoring of effect of biological therapy.
ISSN:0350-199X
1986-5961
DOI:10.5455/medarh.2019.73.374-377